XML 18 R46.htm IDEA: XBRL DOCUMENT v2.4.0.8
BUSINESS COMBINATIONS - Pro forma impact of business combinations (Details) (USD $)
In Millions, except Per Share data, unless otherwise specified
3 Months Ended 6 Months Ended
Jun. 30, 2014
Jun. 30, 2013
Jun. 30, 2014
Jun. 30, 2013
Pro forma of consolidated results of operations        
Revenues $ 2,041.1 $ 1,957.6 $ 3,930.9 $ 3,874.6
Net income (loss) attributable to Valeant Pharmaceuticals International, Inc. $ 127.7 $ (21.5) $ 102.5 $ (104.2)
Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc.:        
Basic (in dollars per share) $ 0.38 $ (0.06) $ 0.31 $ (0.31)
Diluted (in dollars per share) $ 0.37 $ (0.06) $ 0.30 $ (0.31)